As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose, Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health. During his more than 30 years at Pfizer, Albert has built a diverse and successful career, holding several senior positions across a range of markets and disciplines. The global nature of his work – having lived and worked in nine different cities and led teams across five continents – has informed his understanding of the needs of patients and healthcare systems around the world and deepened his commitment to helping ensure equitable access to medicines and vaccines. When he took the reins as CEO in January 2019, Albert accelerated Pfizer’s transformation to become a more science-driven, innovative company – divesting its non-science-based businesses and dramatically increasing its R&D and digital innovation budgets. A powerful example of Pfizer’s capabilities and culture was seen in the company’s response to the COVID-19 pandemic. Refusing to accept public funding and instead investing more than $2 billion dollars at-risk, Albert inspired colleagues to deliver a safe and effective vaccine in just eight months – a process that typically take 8-10 years – without compromising quality or integrity. A year later, continuing to move at the speed of science, Pfizer delivered the first FDA-authorized oral antiviral treatment for COVID-19 by implementing the same sense of urgency and new ways of working that had made the vaccine program so successful. Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is chairman of The Pfizer Foundation and Co-Chair of the Board of Directors for the Partnership for New York City. He is President of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards—Pfizer Inc., PhRMA and Catalyst—and a trustee of the United States Council for International Business. In addition, Albert is a member of the Council on Foreign Relations, the Business Roundtable, the Business Council and the New York City Mayor’s Corporate Council.

2018年6月，安博泰先生担任嘉吉亚太区总裁以及嘉吉亚太农业供应链集团总裁。 安博泰于1983年加入加拿大嘉吉公司，1985年被任命为魁北克南方区销售经理，负责整个公司在魁北克南部的谷物贸易并于1987年在温尼伯担任饲料和粮食贸易经理。1989到1993年期间安博泰在瑞士日内瓦嘉吉国际有限公司任饲料谷物贸易经理直至1993年调任埃及任业务经理。1997年安博泰在嘉吉墨西哥担任董事长及首席驻国代表，直至2005年来到中国担任嘉吉谷物与油籽价值链中国与韩国区总裁。2009年12月，安博泰先生接替退休的前中国区总裁担任该职位。2017年，安博泰先生就任嘉吉农产品供应链北亚区总裁一职。 安博泰积极推动企业社会责任，在他的领导下，嘉吉中国公司的关爱委员会蓬勃发展，嘉吉在各地的志愿活动层出不穷。安博泰本人还在中国担任冰球志愿者教练，为青少年提供冰球培训。

暨南大学毕业，经济学博士，高级工程师，正高级经济师。2005年被评为广东省优秀女企业家，2018年获国务院特殊津贴，2021年起任中国企业改革与发展研究会副会长。 白涛女士先后担任三家省属企业董事长职务，带领团队定战略抓改革促发展、通过制造业当家、兼并重组、资本运作、混合所有制、科技创新、系统化管理等，推动企业高质量发展，取得良好的经济效益和社会效益。

胡伟星，澳门大学社会科学学院院长，澳大发展基金会政治学与公共政策特聘教授。胡教授1983年于北京大学本科毕业，取得法学学士学位。1987年在美国约翰霍普金斯大学获得硕士学位，1992年在美国马里兰大学获得政治学博士学位。曾经在美国加州大学圣地亚哥分校担任过讲师，担任过哈佛大学John M. Olin Fellow和美国布鲁金斯学会客座研究员。 加入澳门大学之前，胡教授长期在香港大学任教，担任香港大学政治与公共行政学系系主任。胡教授曾经担任香港政治学学会主席，香港特区政府中央政策组泛珠三角小组委员，现任全国港澳研究会理事，澳门特区政府公职人员薪酬评议会主席，中美交流基金会顾问，香港海外学人联合会荣誉会长。